Taken together, cetuximab targeting EGFR on HNSCC cells induces potent antibody-dependent cell-mediated cytotoxicity that further augments anti-tumor effect when combined with chemotherapy (Specenier & Vermorken, 2013). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.